These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 7331237)

  • 1. Morbidity by upper respiratory tract diseases in a semi-closed community, after intranasal application of an inactivated influenza vaccine.
    Steiner N; Petrescu A; Mihail A; Steiner G; Călina A
    Virologie; 1981; 32(4):307-9. PubMed ID: 7331237
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of intranasal virosomal influenza vaccine in the prevention of recurrent acute otitis media in children.
    Marchisio P; Cavagna R; Maspes B; Gironi S; Esposito S; Lambertini L; Massimini A; Herzog C; Principi N
    Clin Infect Dis; 2002 Jul; 35(2):168-74. PubMed ID: 12087523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza vaccine oculorespiratory syndrome incidence is reduced in HIV.
    Cooper C; Thorne A;
    Vaccine; 2011 Oct; 29(45):7876-7. PubMed ID: 21872629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Complex studies of virology, microbiology, biochemistry and epidemiology in the adults of a semi-closed community vaccinated against influenza with the inactivated NIVGRIP vaccine intranasally].
    Steiner N; Ionită I; Zaharia CN; Petrescu A; Ciocîrlie I; Stafie D; Dicu A; Stanciu A; Muşat G
    Rev Roum Virol; 1992; 43(1-2):47-58. PubMed ID: 1283825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficiency of the NIVGRIP inactivated influenza vaccine applied by oral route: evaluation in a community of pre-school children in the period 1981-84.
    Coban V; Mihail A; Petrescu A; Teodosiu O; Sternberg I
    Virologie; 1985; 36(2):79-83. PubMed ID: 4036003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
    Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results obtained with the NIVGRIP inactivated influenza vaccine applicable by nasal and/or oral route.
    Petrescu AL; Cajal N
    Virologie; 1984; 35(4):307-14. PubMed ID: 6516213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The virological study of a certified focus of acute respiratory diseases in a half-closed community].
    Steiner N; Mihail A; Berca C; Călina A
    Rev Roum Virol; 1990; 41(3-4):209-11. PubMed ID: 2099831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intranasal inactivated influenza vaccine].
    Tamura S
    Nihon Rinsho; 2006 Oct; 64(10):1871-8. PubMed ID: 17037362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of 4-1BB ligand into an adenovirus vaccine vector increases the number of functional antigen-specific CD8 T cells and enhances the duration of protection against influenza-induced respiratory disease.
    Moraes TJ; Lin GH; Wen T; Watts TH
    Vaccine; 2011 Aug; 29(37):6301-12. PubMed ID: 21704101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ORS during the 2000-2001 influenza vaccination season.
    Choudhri Y; Walop W; Squires S; Tam T; King A; Skowronski D; Warrington R; Wood J
    Can Commun Dis Rep; 2002 Sep; 28(ACS-6):2-8. PubMed ID: 12219588
    [No Abstract]   [Full Text] [Related]  

  • 12. Influenza vaccination by nasal route in a semi-closed community.
    Steiner N; Petrescu A; Teodosiu O; Mihail A; Mihăilescu M; Steiner G; Berca C; Călina A; Soare C
    Virologie; 1980; 31(2):117-20. PubMed ID: 7405010
    [No Abstract]   [Full Text] [Related]  

  • 13. [Intranasal application of inactivated influenza virus vaccines].
    Kuno-Sakai H
    Nihon Rinsho; 1997 Oct; 55(10):2738-45. PubMed ID: 9360400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oculo-respiratory syndrome in association with the influenza vaccine: Canada, October-November 2000.
    Can Commun Dis Rep; 2000 Dec; 26(23):201-2. PubMed ID: 11149349
    [No Abstract]   [Full Text] [Related]  

  • 15. The development of bovine respiratory disease vaccines.
    Phillip JI
    Prog Immunobiol Stand; 1971; 5():304-8. PubMed ID: 4676688
    [No Abstract]   [Full Text] [Related]  

  • 16. Vaccine failure caused an outbreak of equine influenza in Croatia.
    Barbic L; Madic J; Turk N; Daly J
    Vet Microbiol; 2009 Jan; 133(1-2):164-71. PubMed ID: 18632226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-administration of inactivated avian influenza virus with CpG or rIL-2 strongly enhances the local immune response after intranasal immunization in chicken.
    Xiaowen Z; Qinghua Y; Xiaofei Z; Qian Y
    Vaccine; 2009 Sep; 27(41):5628-32. PubMed ID: 19647063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of upper and lower respiratory tract immunity in resistance to Mycoplasma respiratory disease.
    Hodge LM; Simecka JW
    J Infect Dis; 2002 Jul; 186(2):290-4. PubMed ID: 12134269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supplementary statement for the 2002-2003 influenza season: update on oculo-respiratory syndrome in association with influenza vaccination.
    Orr P
    Can Commun Dis Rep; 2002 Sep; 28(ACS-6):1. PubMed ID: 12219587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.